BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 27639373)

  • 1. Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results.
    De Rose F; Fogliata A; Franceschini D; Navarria P; Villa E; Iftode C; D'Agostino G; Cozzi L; Lobefalo F; Mancosu P; Tomatis S; Scorsetti M
    Radiat Oncol; 2016 Sep; 11(1):120. PubMed ID: 27639373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.
    Scorsetti M; Alongi F; Fogliata A; Pentimalli S; Navarria P; Lobefalo F; Garcia-Etienne C; Clivio A; Cozzi L; Mancosu P; Nicolini G; Vanetti E; Eboli M; Rossetti C; Rubino A; Sagona A; Arcangeli S; Gatzemeier W; Masci G; Torrisi R; Testori A; Alloisio M; Santoro A; Tinterri C
    Radiat Oncol; 2012 Aug; 7():145. PubMed ID: 22929062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series.
    De Rose F; Fogliata A; Franceschini D; Iftode C; Torrisi R; Masci G; Sagona A; Tinterri C; Testori A; Gatzemeier W; Fernandes B; Rahal D; Cozzi L; Santoro A; Scorsetti M
    Br J Radiol; 2018 May; 91(1085):20170634. PubMed ID: 29322827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature.
    De Rose F; Fogliata A; Franceschini D; Iftode C; Navarria P; Comito T; Franzese C; Fernandes B; Masci G; Torrisi R; Tinterri C; Testori A; Santoro A; Scorsetti M
    Breast; 2018 Dec; 42():31-37. PubMed ID: 30149235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant breast inversely planned intensity-modulated radiotherapy with simultaneous integrated boost for early stage breast cancer : Results from a phase II trial.
    Meng J; Huang W; Mei X; Yu X; Pan Z; Ma J; Ma X; Chen J; Guo X; Yang Z
    Strahlenther Onkol; 2020 Sep; 196(9):764-770. PubMed ID: 32318767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
    Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
    Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term results of a phase II trial of hypofractionated adjuvant radiotherapy for early-stage breast cancer with volumetric modulated arc therapy and simultaneous integrated boost.
    Franceschini D; Fogliata A; Spoto R; Dominici L; Lo Faro L; Franzese C; Comito T; Lobefalo F; Reggiori G; Cozzi L; Sagona A; Gentile D; Scorsetti M
    Radiother Oncol; 2021 Nov; 164():50-56. PubMed ID: 34537289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated hypofractionated adjuvant whole breast radiation with simultaneous integrated boost using volumetric modulated arc therapy for early breast cancer: A phase I/II dosimetric and clinical feasibility study from a tertiary cancer care centre of India.
    Mondal D; Julka PK; Sharma DN; Jana M; Laviraj MA; Deo SV; Roy S; Guleria R; Rath GK
    J Egypt Natl Canc Inst; 2017 Mar; 29(1):39-45. PubMed ID: 28343538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis.
    De Rose F; Fogliata A; Franceschini D; Iftode C; D'Agostino GR; Comito T; Franzese C; Di Brina L; Clerici E; Loi M; Navarria P; Gatzemeier W; Testori A; Tinterri C; Lobefalo F; Tomatis S; Cozzi L; Scorsetti M
    Clin Breast Cancer; 2020 Dec; 20(6):527-533. PubMed ID: 32665192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity.
    Fiorentino A; Mazzola R; Ricchetti F; Giaj Levra N; Fersino S; Naccarato S; Sicignano G; Ruggieri R; Di Paola G; Massocco A; Gori S; Alongi F
    Cancer Radiother; 2015 Aug; 19(5):289-94. PubMed ID: 26206732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
    Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
    Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.
    Freedman GM; Anderson PR; Goldstein LJ; Ma CM; Li J; Swaby RF; Litwin S; Watkins-Bruner D; Sigurdson ER; Morrow M
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):347-53. PubMed ID: 17379430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis.
    Dong J; Yang Y; Han D; Zhao Q; Liu C; Sun H; Wang Z; Lin H; Huang W
    Technol Cancer Res Treat; 2021; 20():15330338211064719. PubMed ID: 34898315
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant breast radiotherapy using a simultaneous integrated boost: clinical and dosimetric perspectives.
    Alford SL; Prassas GN; Vogelesang CR; Leggett HJ; Hamilton CS
    J Med Imaging Radiat Oncol; 2013 Apr; 57(2):222-9. PubMed ID: 23551785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: the Fox Chase Cancer Center experience.
    Keller LM; Sopka DM; Li T; Klayton T; Li J; Anderson PR; Bleicher RJ; Sigurdson ER; Freedman GM
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):881-7. PubMed ID: 22909414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities.
    Fiorentino A; Gregucci F; Mazzola R; Figlia V; Ricchetti F; Sicignano G; Giajlevra N; Ruggieri R; Fersino S; Naccarato S; Massocco A; Corradini S; Alongi F
    Radiol Med; 2019 Apr; 124(4):309-314. PubMed ID: 30547358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost.
    McDonald MW; Godette KD; Whitaker DJ; Davis LW; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):523-30. PubMed ID: 19775834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Outcomes Using Hypofractionated Tumor Bed Boost Combined With Hypofractionated Whole Breast Irradiation for Early-stage Breast Cancer.
    Yu E; Huang D; Leonard K; Dipetrillo T; Wazer D; Hepel J
    Clin Breast Cancer; 2017 Dec; 17(8):638-643. PubMed ID: 28629952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy boost dose-escalation for invasive breast cancer after breast-conserving surgery: 2093 patients treated with a prospective margin-directed policy.
    Livi L; Meattini I; Franceschini D; Saieva C; Meacci F; Marrazzo L; Gerlain E; Desideri I; Scotti V; Nori J; Sanchez LJ; Orzalesi L; Bonomo P; Greto D; Bianchi S; Biti G
    Radiother Oncol; 2013 Aug; 108(2):273-8. PubMed ID: 23490271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous Integrated Boost Volumetric Modulated Arc Therapy in the Postoperative Treatment of High-Risk to Intermediate-Risk Endometrial Cancer: Results of ADA II Phase 1-2 Trial.
    Macchia G; Cilla S; Deodato F; Ianiro A; Legge F; Marucci M; Cammelli S; Perrone AM; De Iaco P; Gambacorta MA; Autorino R; Valentini V; Morganti AG; Ferrandina G
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):606-13. PubMed ID: 27681755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.